Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling.

Clinical genetics - 1 Aug 2009

Rudnik-Schöneborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Heller R

Abstract excerpt

We reviewed the natural history and assessed the SMN2 copy number of 66 patients with infantile spinal muscular atrophy (SMA) type I born between 2000 and 2005 in Germany whose diagnosis was confirmed by a homozygous SMN1 deletion in the first 6 months of life. After excluding patients who had received valproic acid, the median/mean age at disease endpoint was 6.1/7.3 months (range 0.0-34.0). Four (6.1%) patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Gene Dosage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Counseling

Share to Germany

Share to Spinal Muscular Atrophies of Childhood

Share to Survival of Motor Neuron 2 Protein

Share to Survival Rate

Share to Valproic Acid

Source

Identifiers

PMID: 19780763
DOI: 10.1111/j.1399-0004.2009.01200.x

Genes

SMN2
SMN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling.PMID 19780763Read ↗

Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number.Semantic proximity Read ↗

The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy.Semantic proximity Read ↗

Spinal Muscular Atrophy - Is Newborn Screening Too Late for Children with Two SMN2 Copies?Semantic proximity Read ↗

Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases.Semantic proximity Read ↗

[Natural history of spinal muscular atrophy type I].Semantic proximity Read ↗

Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophySemantic proximity Read ↗

Longitudinal natural history of type I spinal muscular atrophy: a critical review.Semantic proximity Read ↗

The influence of genotype on the natural history of types 1 - 3 spinal muscular atrophySemantic proximity Read ↗

Insights into genotype-phenotype correlations in spinal muscular atrophy: a retrospective study of 103 patients.Semantic proximity Read ↗

Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next.Semantic proximity Read ↗

Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis.Semantic proximity Read ↗

Spinal muscular atrophy: A changing phenotype beyond the clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.